dc.contributor.author | ÜNAL, SERHAT | |
dc.contributor.author | Erdinc, Sebnem | |
dc.contributor.author | Tabak, Fehmi | |
dc.contributor.author | Gül, Ahmet | |
dc.contributor.author | Alp, Emine | |
dc.contributor.author | Sevgi, Dilek Yildiz | |
dc.contributor.author | Cagatay, Arif Atahan | |
dc.contributor.author | Bozkurt, Ilkay | |
dc.contributor.author | Yasar, Kadriye Kart | |
dc.contributor.author | Senoglu, Sevtap | |
dc.contributor.author | HASANOĞLU, İMRAN | |
dc.contributor.author | Guner, Rahmet | |
dc.contributor.author | Celik, Ilhami | |
dc.contributor.author | KANAT, FİKRET | |
dc.contributor.author | Batirel, Ayse | |
dc.contributor.author | TELLİ DİZMAN, GÜLÇİN | |
dc.contributor.author | Eren, Esma | |
dc.contributor.author | KAZAK, ESRA | |
dc.contributor.author | KARAALİ, RIDVAN | |
dc.contributor.author | Celikbas, Aysel | |
dc.contributor.author | PULLUKÇU, HÜSNÜ | |
dc.date.accessioned | 2023-02-21T10:08:32Z | |
dc.date.available | 2023-02-21T10:08:32Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | HASANOĞLU İ., Guner R., Celik I., KANAT F., Batirel A., TELLİ DİZMAN G., Eren E., Sevgi D. Y., Bozkurt I., Yasar K. K., et al., "Remdesivir treatment for patients with moderate to severe COVID-19", TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.4, ss.880-887, 2022 | |
dc.identifier.issn | 1300-0144 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_3d334c46-090c-4756-831a-41c821b37654 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/188135 | |
dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/3d334c46-090c-4756-831a-41c821b37654/file | |
dc.identifier.uri | https://doi.org/10.55730/1300-0144.5387 | |
dc.description.abstract | Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment. | |
dc.language.iso | eng | |
dc.subject | Patofizyoloji | |
dc.subject | Temel Bilgi ve Beceriler | |
dc.subject | Değerlendirme ve Teşhis | |
dc.subject | Dahiliye | |
dc.subject | Aile Sağlığı | |
dc.subject | Tıp (çeşitli) | |
dc.subject | Genel Tıp | |
dc.subject | TIP, GENEL & DAHİLİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Temel Tıp Bilimleri | |
dc.subject | Genel Sağlık Meslekleri | |
dc.title | Remdesivir treatment for patients with moderate to severe COVID-19 | |
dc.type | Makale | |
dc.relation.journal | TURKISH JOURNAL OF MEDICAL SCIENCES | |
dc.contributor.department | İstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü | |
dc.identifier.volume | 52 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 880 | |
dc.identifier.endpage | 887 | |
dc.contributor.firstauthorID | 4077201 | |